Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost

Código QR

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost

Gregory Katz1, Clark L Springs2, E Randy Craven3, Michela Montecchi-Palmer41Huron Ophthalmology, Ypsilanti, MI, USA; 2Indiana University Eye Care, Indianapolis, IN, USA; 3Specialty Eye Care, Denver, CO, USA; 4Alcon Research Ltd., Fort Worth, TX, USAPurpose: The preservative benzalkonium chloride (BA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gregory Katz, Clark L Springs, E Randy Craven, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/00b02c5548164ac9a8213df7afbad1b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Sophia K Mirza, et al.
Publicado: (2010)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: David A Godfrey, et al.
Publicado: (2009)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado AS, et al.
Publicado: (2011)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Michael J Miyashiro, et al.
Publicado: (2010)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue K, et al.
Publicado: (2012)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella F, et al.
Publicado: (2012)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
por: Emilio Rintaro Suzuki Jr, et al.
Publicado: (2010)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: J Charles Henry, et al.
Publicado: (2008)

Corrigendum: Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
por: Suzuki CLB, et al.
Publicado: (2010)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner SF, et al.
Publicado: (2019)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial
por: Dai Woo Kim, et al.
Publicado: (2021)

BAK additive influence on results
por: Shah RD, et al.
Publicado: (2013)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
por: Lanzl I, et al.
Publicado: (2013)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão MLS, et al.
Publicado: (2014)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo J, et al.
Publicado: (2016)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
por: Ermiş&nbsp;SS
Publicado: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Douglas J Rhee, et al.
Publicado: (2008)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe T, et al.
Publicado: (2016)

Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
por: Bhagat P, et al.
Publicado: (2014)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
por: Figueiredo BP, et al.
Publicado: (2013)

Topical Medication Therapy for Glaucoma and Ocular Hypertension
por: Tao Wang, et al.
Publicado: (2021)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Dostoevsky’s Works in Modern Azerbaijan. Pedagogical Readings in Bak
por: Kjamalya A. Umudova
Publicado: (2019)

Paradoxical implication of BAX/BAK in the persistence of tetraploid cells
por: Jiayin Deng, et al.
Publicado: (2021)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi M, et al.
Publicado: (2014)

Tolerability and effectiveness of preservative-free dorzolamide&ndash;timolol (preservative-free Cosopt&reg;) in patients with open-angle glaucoma or ocular hypertension
por: Cindy Hutnik, et al.
Publicado: (2010)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano T, et al.
Publicado: (2016)

Characterization of an alternative BAK-binding site for BH3 peptides
por: Kaiqin Ye, et al.
Publicado: (2020)

Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies
por: Sweta Iyer, et al.
Publicado: (2016)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
por: Takemoto D, et al.
Publicado: (2017)

Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study.
por: Hong Liang, et al.
Publicado: (2012)

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
por: Dimitris Papaconstantinou, et al.
Publicado: (2009)

Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone
por: M Selim Kocabora, et al.
Publicado: (2008)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
por: Anna Galanopoulos, et al.
Publicado: (2008)

Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital
por: Edmund P Farris
Publicado: (2008)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue K, et al.
Publicado: (2012)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: E Randy Craven, et al.
Publicado: (2010)